AstraZeneca antidepressant is dumped after trial failures
AstraZeneca's already thin drugs pipeline was battered again yesterday when the pharmaceuticals firm admitted that an experimental antidepressant, once hailed as a potential worldwide multibillion dollar-a-year blockbuster, had failed its latest clinical trials and would be dumped.
It is another blow for Britain's second-biggest pharmaceuticals company, which last year called off late-stage trials of a prostate cancer drug, before writing off $445m (£281m) as it abandoned a new respiratory medicine for children.
Meanwhile Astra is facing a "patent cliff" as current blockbusters begin to face generic competition.
The drug maker will take a $50m impairment charge for the failure of TC-5214, which it licensed from the biotech Targacept three years ago for up to $1.2bn, dependent on hitting targets.
Astra had hoped that the drug would be the first in a new class of mental health medicines that work by calming nicotine receptors in the brain and it paid $200m up front for the rights.
Strong results from a Phase II study gave it pole position in AstraZeneca's prospective drugs portfolio, but TC-5214 failed the first of two late-stage trials last year, prompting an initial $96.5m writedown.
Now Astra has entirely abandoned its application to get the drug licensed for use as anadd-on therapy for patientswith depression.
AstraZeneca has just one drug in development, fostamatinib for arthritis, that analysts believe could be a big hit.
This month, the patent will expire on Seroquel, the anti-psychotic drug which brought in revenues of $5.7bn last year. Its ulcer treatment Nexium, which contributed $4.4bn to 2011 sales, faces competition in America in 2014 and its $6.6bn-a-year cholesterol-buster Crestor goes off patent in 2016.
Oscar Pistorius trial: Defence's own witness contradicts athlete's version of events
Oscar Pistorius trial: The case against Oscar Pistorius – and why the prosecution claims his story doesn't add up
Almost 40m gallons of drinking water discarded – because a man urinated in it
Peaches Geldof funeral: Private ceremony to be held at same place as her mother Paula Yates on Easter Monday
Shropshire criminals ‘using unmanned drones and infrared cameras to find illegal cannabis farms’ – and then steal from the growers
The food poverty scandal that shames Britain: Nearly 1m people rely on handouts to eat – and benefit reforms may be to blame
US Navy christens huge $3 billion destroyer ship USS Zumwalt that appears as a fishing boat on enemy radar
Scottish independence: It is the English who should be on their knees, begging the Scots to vote ‘No’
Nigel Farage fatigue? Half of voters ‘immune’ to Ukip’s appeal
Nigel Farage on Have I Got News For You: Ukip leader ridiculed over expenses and party 'fruitcakes'
Nigel Farage: I’m taking on the status quo, and the Establishment’s fighting back
- 1 Are you turning into your dad? The top ten signs you've embraced dad-ism revealed as survey says 38 is age men turn into their father
- 2 Video of British Muslims dancing to Pharrell Williams's hit Happy attacked as 'sinful'
- 3 Overheard in Waitrose: documenting the chatter in 'Britain's poshest supermarket'
- 4 24 people applied for the 'world's toughest job', here are their interviews
- 5 Grace Dent on TV: Game of Thrones has jumped the shark
iJobs Money & Business
£150.00 per week: QA Apprenticeships: This company has been providing on site ...
£221.25 per week: QA Apprenticeships: This company is a well established Inter...
£40000 - £50000 per annum: Harrington Starr: Client Relationship Manager - SQL...
£35000 - £50000 per annum: Pro-Recruitment Group: Take your chance to join the...